Axogen Inc vs First Citizens BancShares Inc — how do they compare? Axogen Inc trades at $47.92 (market cap $2.67B), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.26B). The key difference: First Citizens BancShares Inc is far larger — about 9.5× Axogen Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | FCNCA | |
|---|---|---|
Market Cap | $2.67B | $25.26B |
Sector | Technology | Sector/Thematic |
52-Week High | $49.67 | $2.27K |
52-Week Low | $14.79 | $1.64K |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 2.45% today, showing strong momentum near resistance at $50. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth remains robust with Q2 2026 sales up 23.1% to $69.7 million and full-year guidance raised to at least $279 million, but profitability challenges persist with negative net margins and recent earnings misses.
Analyst consensus remains strongly bullish with 84% buy ratings and a $54.33 price target, representing 9.4% upside potential. Key investment opportunities include expanding nerve care platform adoption and reimbursement improvements, while risks include ongoing profitability challenges, competitive pressures, and reliance on elective procedure recovery.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.
FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →